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Abstract: Drug delivery systems (DDS) are able to deliver, over long periods of time, 
therapeutic concentrations of drugs requiring frequent administration. Two classes of DDS 
are available, biodegradable and non-biodegradable. The larger non-biodegradable 
implants ensure long-term delivery, but require surgical interventions. Biodegradable 
biomaterials are smaller, injectable implants, but degrade hydrolytically and release drugs 
in non-zero order kinetics, which is inefficient for long-term sustained drug release. 
Biodegradable poly(ester amides) (PEAs) may overcome these difficulties. To assess their 
ocular biocompatibility and long-term behavior, PEA fibrils were analyzed in vitro and  
in vivo. In vitro, incubation in vitreous humor changes to PEA structure, suggests 
degradation by surface erosion, enabling drug release with zero order kinetics. Clinical and 
histological analysis of PEA fibrils implanted subconjunctivally and intravitreally showed 
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the absence of an inflammatory response or other pathological tissue alteration. This study 
shows that PEA fibrils are biocompatible with ocular environment and degrade by  
surface erosion. 
Keywords: biomaterials; biodegradation; drug delivery; controlled drug release; amino acid 
 
1. Introduction 
Ocular drug delivery is a rapidly expanding pharmaceutical market and a key target area for the 
pharmaceutical industry. An unmet need in ocular drug delivery is the sustained, zero order delivery of 
drugs and other bioactive molecules to the posterior segment of the eye [1]. Successful ophthalmic 
therapy requires that an effective concentration reaches the specific target tissue. This is particularly 
difficult when the target tissue is the posterior segment, since, when applied to the cornea, most drugs 
do not penetrate in sufficient quantity to the posterior segment [2]. Treatment of posterior segment 
disorders often requires the administration of drugs over extended periods of time, which is usually 
achieved by injection of the drug as close to the diseased tissue as possible. For exudative age-related 
macular degeneration (AMD), choroidal neovascularization is controlled by monthly intravitreal 
injections of anti-VEGF (vascular endothelial growth factor) throughout the life of the patient, with 
substantial risk of side effects including endophthalmitis and ocular hypertension [3–6]. 
To avoid the complications associated with frequent intraocular injections, a sustained-release drug 
delivery device would be required. Sustained intraocular drug delivery systems (DDS), that allow the 
long-term release of the active substance with the same therapeutic effect as multiple injections, are 
available, but have not proven satisfactory. One of the first non-degradable intraocular sustained drug 
delivery biomaterials, Vitrasert® (Bausch & Lomb), was approved by the FDA (U.S. Food and Drug 
Administration) and introduced to the market in 1996 for the treatment of cytomegalovirus (CMV) 
retinitis in patients infected with human immunodeficiency virus [2,7]. Vitrasert® releases the antiviral 
drug ganciclovir over five to eight months. However, a number of complications associated with  
non-biodegradable materials, such as surgical removal of depleted inserts, visual acuity loss, vitreous 
humor hemorrhage, retinal detachment, vitreous humor detachment, vitreous humor traction, hypotony, 
severe post-operative inflammation, etc. and non-compatibility with protein drugs have prevented the 
wide use of non-biodegradable materials for intraocular therapy [8–10]. 
Currently, micro- and nanoparticles prepared from linear, biodegradable polyesters such as 
poly(lactic-co-glycolic acid) (PLGA) are used [11] and in 2009 an injectable PLGA intravitreal insert, 
OZURDEX®, was approved by the FDA and is used successfully for the treatment of macular edema 
by releasing dexamethasone over a period of about three months [2,12]. PLGA is not used widely for 
intraocular drug delivery, in part because the kinetics of degradation and drug release are irregular. 
There is an initial burst of drug release, followed by a phase of sustained release and a final phase in 
which all remaining drug is set free [1,13]. In addition to the asymmetrical release of drug, PLGA is 
hydrolyzed into lactic acid and glycolic acid, which transiently decrease vitreous humor to pH 7 and 
increases the risk of inflammation before being metabolized [12,14]. In addition, PLGA has been 
reported to show low compatibility with acid sensitive bio-pharmaceuticals [14,15]. 
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Ideally a DDS should be compatible with all or most drugs and its degradation should enable a 
zero-order drug release for efficient treatment. Degradation of the DDS should occur over an  
extended period of time to provide the patient effective treatment. A new class of amino acid based 
poly(ester amide) (PEA) polymers have been developed that meet the requirements of an efficient and 
useful drug delivery system [16–20]. 
PEAs are synthetic polycondensation products consisting of biocompatible building blocks such as 
hydrophobic L-amino acids, aliphatic di-carboxylic acids and α,ω-diols. The use of amino-acids as 
components of the PEA polymers confers several advantages. Degradation in vivo is accomplished by 
enzymes normally present in tissues, degradation begins at the surface allowing controlled zero order 
degradation [21,22], drugs are released with a zero order kinetics and the incorporation of amino  
acid-based building blocks [20] provide one or more functional groups along the polymer chain 
allowing modification of the polymer to tailor its physical and chemical properties, bio-erosion and 
performance as drug releasing vehicles, e.g. [16]. Recently, this class of polymers have been shown to 
be compatible with the cardiovascular environment [18,19] and successfully applied as drug eluting 
coating on coronary stents [18]. 
However, most of the work done on PEA polymers has been limited to in vitro analysis and rare  
in vivo works investigations to coat cardiovascular stents. To our knowledge, solid PEA fibers have not 
been examined as an implantable drug delivery system. The ability to encapsulate and release a variety 
of drug species, including protein drugs, coupled with the lack of side effects of degradation products 
and versatile processability of the PEA polymers to be manufactured as injectable fibrils and 
microparticles, makes PEA platform ideal as a vehicle for the prolonged delivery of ophthalmic drugs. 
Here we report the development of PEA microfibrils as ocular implants, and shown that the studied 
PEA polymer can be effectively extruded to injectable microfibrils with therapeutic potential for 
ophthalmology. Furthermore, PEA microfibrils were implanted in rabbits subconjunctivally and 
intravitreally by injection and shown to be well tolerated for the studied period up to eight weeks 
triggering only healthy inflammatory responses. The fibrils degrade by surface erosion in presence of 
proteases which makes them attractive for further research as a potential long-term drug eluting device. 
2. Experimental Section 
2.1. Polymer Preparation 
Unless specified otherwise, all chemicals were purchased from Sigma-Aldrich (St. Louis, MI, USA). 
1H NMR analysis was performed on a Varian Inova 300 spectrometer (Varian Inc./Agilent 
Technologies, Santa Clara, CA, USA) using a 10 mg/mL polymer solution in deuterated chloroform. 
Differential scanning calorimetry (DSC) was performed using a Mettler Toledo 822e DSC (Mettler 
Toledo, Greifensee, Switzerland) connected to an Intercooler and an auto robot TS0801RO (Mettler 
Toledo, Greifensee, Switzerland). 
Polymer molecular weight and polydispersity were evaluated by means of gel permeation 
chromatography (GPC) on Waters separations module with column heater type e2695 (Waters, 
Milford, CT, USA) and Waters RI detector type 2414 (Waters). A styragel HR5E and styragel HR2 
with a guard column at 50 °C were used (Waters). As an eluent tetrahydrofuran (THF) with a flow rate 
Polymers 2014, 6 246 
 
 
of 1.0 mL/min and an injection volume of 100 μL was applied. Calculations were done relatively to 
polystyrene calibration standard. 
The polymer used in this study was synthesized following the procedure reported by Katsarava [23]. 
Briefly, the polymer was prepared via polycondensation of 0.45 equivalents of di-p-toluenesulfonic 
acid salts of bis-(L-leucine)1,4-dianhydro sorbitol diester (1), 0.30 equivalents of bis-(L-leucine)  
α,ω-hexane diol-diester (2), 0.25 equivalents of lysine benzyl-ester (3), and one equivalent of  
di-N-hydroxysuccinimide ester of sebacic acid (4) in anhydrous DMSO and triethylamine added in a 
glass vessel with overhead stirrer under a nitrogen atmosphere (Figure 1). The usage of pre-activated 
acid in the reaction allows polymerization at relative low temperature (65 °C; 48 h) resulting in  
side-products-free polycondensate and predictable degradation products. The polymer was isolated 
from the reaction mixture in two precipitation steps resulting in a white amorphous material of 54 kDa 
average number molecular weight (Mn). The relative ratio of the different building blocks in the 
polymer was calculated from the 1H NMR spectrum. The integration of characteristic protons signals for 
1,6-hexanediol (m, 4.1–3.9 ppm), lysine (m, 3.0–2.9 ppm) and 1,4:3,6-dianhydro-D-sorbitol (s, 4.7 ppm) 
was used to calculate the relative molar ratio of the amino acid containing building blocks (Figure 2). 
The results are shown in Table 1 reveal that actual copolymer composition is very close to the 
theoretical one. To obtain a uniform mixture, the polymer was cryomilled in Retsch ZM200 (Retsch, 
Haan, Germany) equipment in the presence of 0.25% w/w fluorescein octadecyl ester and 0.25% w/w 
ascorbic acid as an antioxidant. 
Figure 1. The poly(ester amide) (PEA) polymer is synthesized from the four monomers: 
bis-(L-leucine) 1,4-dianhydro sorbitol diester (1), bis-(L-leucine) α,ω-hexane diol-diester (2), 
lysine benzyl-ester (3), and di-N-hydroxysuccinimide ester of sebacic acid (4). 
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Table 1. Content of the amino acid containing building blocks in the final polymer. 
Figure 2. 1H NMR spectrum of PEA III Ac Bz recorded in deuterated chloroform. The 
integration of characteristic protons signals at 4.7 ppm (s), 4.1–3.9 ppm (m), and  
3.0–2.9 ppm (m) has been used to determine the relative molar ratio of the amino acid 
containing building blocks in the polymer chain. 
 
The cryomilled polymer was processed into fibril with a Xcelera mini-extruder (Xcelera, 
Philadephia, PA, USA) equipped with a DSM (Geleen, The Netherlands) micro fiber spin device for 
thin fibril spinning. Following 5–10 min residence time at 140 °C the polymer was stretched into 
fibrils of 120–300 µm in diameter. The extrusion was performed under nitrogen to minimize further 
oxidative degradation of the polymer. The fibrils were cut into 4 mm segments and sterilized by gamma 
irradiation (25 kGy) under cooling conditions by BGS Beta-Gamma-Service GmbH (Wiehl, Germany). 
2.2. Degradation of PEA Fibrils by α-Chymotrypsin 
Degradation of the PEA fibrils was analyzed by incubation in a solution of α-chymotrypsin (0.15 
mg/mL, 8.5 units, type II, lot #060M7007V) in 0.1 M PBS (phosphate-buffered saline) buffer (pH 7.4) 
at 37 °C with gentle shaking (100 rpm). The chymotrypsin solution was replaced every 3-4 days to 
maintain a constant level of enzyme activity and to prevent inhibition of the enzyme by degradation 
products. Sodium azide (0.05 wt%) was added to prevent bacterial contamination. After two weeks the 
surface of the polymer fibrils was analyzed by scanning electron microscopy (SEM). 
Monomers Theoretical content (mol %) Content determined by 1H NMR (mol %) 
1 45 42 
2 30 32 
3 25 26 
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2.3. Degradation of PEA Fibrils by Vitreous Humor in Vitro 
PEA fibrils were incubated in PBS (control), rabbit, human and bovine vitreous humor at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2. Experiments were performed in triplicate and fibrils 
were analyzed weekly by fluorescence microscopy. At day one and three, and at four and eight weeks, 
fibrils were collected and examined by SEM for surface alterations. Vitreous humor was collected 
from Eye Bank donor eyes after obtaining appropriate informed consent. All experiments involving 
human tissue were conducted with approval of the institutional ethics committee. 
2.4. Intravitreal and Subconjuctival Implantation and Clinical Follow Up 
Female Chinchilla Bastard Rabbits (Charles River Company, Sulzfeld, Germany) with an average 
body weight of 2–3 kg were used. All animal experiments were conducted in accordance with the 
principles for the care and use of research animals and were carried out with the permission and 
supervision of the Office for the Nature, Environment and Consumer Protection (LANUV), 
Recklinghausen, Germany. For subconjunctival implantation a radial incision was made into the rabbit 
conjunctiva and a chamber was prepared by dissecting the conjunctiva from the sclera. One or two dry 
fibrils were placed into the chamber and the incision was closed with one Vicryl™ 9-0 suture (Ethicon, 
Somerville, MA, USA). The implants were observed weekly during a follow up of 1, 2, 4 or 8 weeks. 
For intravitreal implantation of dry fibrils, a transscleral paracenthesis was made with a 26 G needle 
1.5 mm below the limbus and a modified 26 G intravenous catheter (BD, Franklin Lakes, NJ, USA) 
inserted (Figure 3). After removing the catheter needle the PEA fibril was inserted to the catheter with 
micro forceps and moved forward with the catheter needle into the vitreous humor. The catheter was 
removed and the intravitreal position of the fibril was documented by video photography (Figure 4). 
PEA fibrils were explanted after 1, 3 or 5 days and after 2, 4 or 8 weeks. Clinical examinations by 
funduscopy were done weekly to confirm presence and shape of the fibrils and to observe the status of 
the fundus. 
At specified times eyes were enucleated and after macroscopic observation, the subconjunctival 
implants and surrounding tissue were subjected to histological analysis. Intravitreal fibrils were 
explanted, air dried and stored at 4 °C for SEM examination. 
Figure 3. (A) About 1.5 mm below the limbus a transscleral paranthesis was done and a 
modified catheter inserted. (B) By pushing forward the fibril with the catheter needle the 
polymer was implanted into the vitreous. 
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Figure 4. Intravitreal implantation of a dry PEA fibril in rabbits. Note that the fibril 
(arrow) is still in contact with the catheter protruding into the vitreous humor. 
 
2.5. Histology 
The subconjunctival PEA implants and surrounding tissue were fixed in 3.7% formalin and 
embedded in paraffin. Five micrometer thick sections were stained with H&E (hematoxylin and eosin) 
and analyzed for signs of inflammation and tissue reactions. Retinae from eyes with intravitreal 
implants were fixed in 3.7% formalin, embedded in paraffin, sectioned, stained with H&E and 
examined microscopically to evaluate the influence of PEA fibrils on retinal morphology and integrity. 
2.6. Statistics 
All experiments were done at least in triplicate and means ± SEM were calculated. To compare two 
parameters in repeated measurements of three groups, the two-way ANOVA (Analysis of Variance) 
with the Bonferroni correction was performed using the GraphPad Prism 5 (GraphPad Inc., San Diego, 
CA, USA) software. 
3. Results and Discussion 
Biomaterials are used in several clinical applications, e.g., joint replacement by metal-based 
materials [24], heart valves [25], blood vessel prosthesis [26,27], breast implants [28], as well as for 
drug delivery, such as delivery of subcutaneous contraceptives [29] among others. In ophthalmology 
biomaterials are used extensively as intraocular lenses and contact lenses and since 1996 with the 
approval by the FDA of Vitrosert® (Bausch & Lomb), an intravitreal implantable biomaterial, has been 
used to deliver ganciclovir for the treatment of CMV retinitis in patients with acquired 
immunodeficiency syndrome (AIDS). Since 1996 a number of biomaterial devices have been 
developed for intravitreal implantation and are currently in use, such as Ozurdex® (Allergan, Inc., 
Irvine, CA, USA) [30], Surodex (Allergan, Inc., Irvine, CA, USA) [31,32], Retisert® (Bausch & Lomb, 
Inc., Rochester, NY, USA) [33] or Iluvien® (Alimera Sciences, Alpharetta, GA, USA) [34]. However, 
many of these biomaterials have significant limitations. Non-biodegradable materials for drug delivery 
devices are large, multicomponent, require surgeries for implantation and must be surgically removed 
when depleted. Biodegradable materials such as Ozurdex®, which can be injected into the vitreous humor, 
release the drug irregularly. Additionally, the degradation products cause transient acidification of the 
vitreous humor and are not compatible with many drug species, such as biological therapeutics [1,12,15]. 
Ideally, a biomaterial for drug delivery should release the drug in a sustained, zero order kinetics, 
should be compatible with a large number of drugs and biological therapeutic products; the 
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degradation products of the biomaterial should not cause any alterations at the implant site or adjacent 
tissues, and for ophthalmic use the drug-loaded biomaterial should be injectable. PEAs appear to have 
many of these characteristics, e.g., are capable of sustained drug release and degrade enzymatically by 
surface erosion [21] and in addition, can be functionalized to meet a wide spectrum of purposes. 
3.1. Effect of Chymotrypsin on Fibril Surface Morphology 
We have treated PEA fibrils with chymotrypsin and shown by SEM that the surface of the fibrils 
eroded while leaving the core of the fibril intact in agreement with earlier studies [22]. Although 
chymotrypsin is a digestive system enzyme, it degrades proteins hydrolytically in a manner similar to 
enzymes present in ocular tissues including the vitreous humor [17,35]. Proteomic analyses has 
confirmed the presence of a number of enzymes in the vitreous humor such as carbonic anhydrase, the 
glutathione peroxidase or the prostaglandin D2 synthase [36], and 51 proteases, some of which show 
increases in diseases like the diabetic retinopathy [37–40]. Contrary to the degradation of  
PLGA [1], which takes place in the bulk via cleavage of its backbone ester linkages into oligomers and 
finally monomers [13], degradation of PEA fibrils appears to take place by surface erosion, suggesting that 
barrier properties of PEA matrix will be preserved during the entire life-time of the implant [22], a 
characteristic that would allow PEAs to be used for the fabrication of long-term, controlled release devices. 
After two weeks of incubation in chymotrypsin the fibrils appear uneven with rough surface and 
significant patterns of erosion (Figure 5A) whereas the surface of fibrils incubated in PBS is smooth 
with no sign of degradation (Figure 5B). Both in chymotrypsin and PBS gross examination revealed 
that the fibrils were considerably shorter in length and increasing in diameter (see below). 
Figure 5. (A) After two weeks exposure to α-chymotrypsin, there has been obvious erosion 
of the PEA fibril, as evidenced by the frayed appearance of the fibril surface in SEM 
micrographs. (B) No evidence of any change was noted in fibrils incubated in PBS. 
 
3.2. Effect of Vitreous Humor on Fibril Morphology 
Incubation of PEA fibrils for eight weeks in rabbit vitreous humor (Figure 6) resulted in a mottled 
surface suggesting surface erosion, whereas in human vitreous humor (Figure 7) only rounding of the 
cut edges of the fibrils suggesting shape changes. The differential effect of rabbit and human vitreous 
humor on the structure of PEA fibrils may result from differences in enzymatic content between 
human and rabbit vitreous humor. 
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Figure 6. (A–C) In PBS, fibrils show rounding and smoothing of the edges after an initial 
shortening; (D–F) whereas the fibrils incubated in rabbit vitreous humor (rbVitreous) after 
the initial shortening, show erosive changes, as evidenced by the mottled appearance of the 
fibrils. Scale bar, 500 µm. Magnification, 50×. 
 
Figure 7. (A–C) Morphology of PEA fibrils after incubation in human vitreous humor. As 
in rabbit vitreous humor, fibrils incubated in human vitreous humor contract, but at eight 
weeks show less erosion changes. Scale bar, 500 µm. Magnification, 50×. 
 
By eight weeks of incubation in rabbit vitreous humor, the surface appeared mottled covering the 
surface, suggesting erosion of the fibril structure (Figure 6F). However, in human vitreous humor the 
surface seemed unaltered (Figure 7C). 
3.3. Remodeling of Fibrils in Aqueous Environments 
Subjection of PEA fibrils to aqueous solutions such as PBS, as well as vitreous humor, resulted in 
distinct remodeling within 24 h (Figures 6–8). The PEA fibrils keep their shapes, obtained by 
extrusion, at dry stage since the glass transition temperature (Tg) of the polymer is well above the 
ambient temperature (room temperature of about 24 °C). Once, however, exposed to aqueous 
environment the polymeric material gets plasticized by water, glass transition temperature drops below 
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the temperature of the experiment (37 °C) and fibers start to remodel driven by the tension introduced 
via extrusion process. The remodeling is relatively quick within 24 h, following the fibril exposure to 
water and occurs in both vitreous fluid and PBS. The event is not related to degradation since the fibril 
shows neither weight loss nor changes in the molecular weight of the polymer. 
Figure 8. (A) Fibrils incubated in bovine vitreous humor, in rabbit vitreous humor, or in 
PBS, shorten by 70% (from 4.03 to 1.19 mm) and (B) increase in diameter by 81% (from 
173 to 311 µm) within the first 2 h. During the following 22 h the fibrils continue to 
shorten but to a much lesser extent (7.3 %) and reach minimal length and maximal 
diameter by 24 h. No significant difference in remodeling time and manner among bovine 
vitreous humor, rabbit vitreous humor or PBS (two-way ANOVA). Data is displayed as 
mean ± SEM (n = 3). 
 
This change in shape of the fibrils in vitreous humor and PBS suggests that PEA fibrils would be 
useful as drug delivery devices, because drug loaded fibrils could be injected into the vitreous humor 
where they would remodel, allowing a lower surface to volume ratio (Table 2) thus decreasing adverse 
side effects related to implant size. Whether drug-loaded fibrils would remodel in a similar fashion 
without releasing the drug will need to be evaluated. 
Table 2. The surface/volume ratio of the PEA fibrils decreased from 22–24 before 
incubation to 13–16 after 2 h of incubation in PBS or vitreous humor. 
Liquid  Incubation time Surface / volume ratio 
PBS 0h 22.7 
2h 13.8 
Rabbit vitreous humor 0h 24.0 
2h 15.8 
Bovine vitreous humor 0h 24.0 
2h 14.4 
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In detail, in PBS, rabbit, human (Figures 6A–F, 7A–C and 8A,B) and bovine vitreous humor 
(Figure 8A,B) the fibrils become considerably shorter and thicker within 24 h with no evident surface 
alterations. To quantify the change in shape in PBS, rabbit and bovine vitreous humor the length and 
the diameter of the fibrils (n = 3) was measured before and after 2 h and 24 h of incubation (Figure 9). 
The fibrils were photographed, and length and diameter determined with the Diskus imaging software 
(Hilgers, Germany). 
Figure 9. (A–C) Follow-up of PEA fibrils implanted in the rabbit conjunctiva. During the 
eight weeks of the experiment, no abnormalities and only few signs of inflammatory 
reactions were observed at the site of implantation. Note the clear conjunctiva with the 
fibril clearly visible (arrows). (D) The inset shows a normal implantation site of an 
enucleated eye with the fibril (arrow) clearly visible eight weeks after implantation. 
  
During the first 2 h the fibrils decreased in length from 4.10 to 1.17 mm (or by 72%) in PBS, from 
4.02 to 1.32 mm (or by 67%) in rabbit vitreous humor and from 3.96 to 1.08 mm (or by 72%) in 
bovine vitreous humor. During the first 2 h the fibrils also increased in diameter from 181.7 to 330.7 µm 
(or by 85%) in PBS, from 170.8 to 279.7 µm (or by 63%) in rabbit vitreous humor and from 167.2 to 
323.3 µm (or by 95%) in bovine vitreous humor. During the next 22 h of measurements the fibrils 
decreased in length by only 5% in PBS, by 5% in rabbit vitreous humor and by 12% in bovine vitreous 
humor and increased in diameter by 9% in PBS, by 18% in rabbit vitreous humor and by 7% in bovine 
vitreous humor (Figure 8). 
3.4. Biocompatibility of PEA in Conjunctival Tissue 
PEAs have been proposed as drug delivery vehicles and in vitro studies have shown that PEAs are 
not toxic [41,42] and, as we report here, become degraded by surface erosion. However, it is not 
known how these polymers behave in vivo in relation to toxicity, immunological response, degradation 
and morphological architecture. To define the effects of the ocular environment PEA fibrils were 
implanted in the vitreous humor and subconjunctivally in rabbits. 
No inflammatory reactions were observed by direct examination or by video documentation of the 
fibrils implanted subconjunctivally during the eight weeks of the experiments. Shown in Figure 9 are 
photographs captured from the videos at 1, 4 and 8 weeks; note that at one week (Figure 9A) in this 
particular implant a mild vascular reaction is evident, which is especially pronounced at the site of the 
suture and not in the immediate vicinity of the implanted fibril (arrow). A similar mild inflammatory 
response was observed in one third of the implants, which in all cases resolved by the fourth week. 
Figure 9B–D show an implant at 4 and 8 weeks after implantation; note that there are no signs of 
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inflammation; the tissue surrounding the PEA fibril is free of new vessels, edema or other indications 
for inflammation. Similar to our in vitro data, PEA fibrils showed considerable reshaping after 
subconjunctival implantation; within 24 h the fibrils become considerably shorter and thicker. 
3.5. Histology of Fibrils and Subconjunctival Implantation Site 
After enucleation, 84% of the subconjunctival PEA implants were located, explanted with 
surrounding tissue, and processed for histology. H&E staining showed that by week one a thin capsule 
had formed around the implanted fibrils (Figure 10) which persisted throughout the eight weeks of the 
experiment. Cells at the capsule edge were fibroblasts, with granulation tissue evident in some 
specimens. Along the capsule and adjacent to the implant site, lymphocytes and macrophages were 
observed (arrows) indicating a mild, normal tissue reaction to a foreign material and at week one a 
single plasma cell was observed at the implant site. However the total number of inflammatory cells 
remained low for the eight weeks of follow-up indicating only a slight immunological reaction. No 
giant cells or eosinophils were observed in the vicinity of the implant. The thin capsule clearly 
demonstrates the excellent biocompatibility of PEA polymers, but raises the question of permeability 
of the drug released by the PEA fibrils through the capsule. Studies of drug concentration in the tissue 
adjacent to implanted drug loaded microfibrils will be carried out to answer this question. 
Figure 10. (A) Histology of the subconjunctival implant site. By week one after the 
implantation of the PEA fibrils, a thin capsule (asterisk) had enveloped the fibril; (B,C) the 
capsule persisted for the eight weeks of the experiment. Fibroblasts were consistently 
observed adjacent to the capsule. Rare leukocytes are visible in the magnified sections 
(examples are marked with arrows). Scale bar, 200 µm. Magnification, 200×. 
 
Summarized, histological analysis of the fibrils and subconjunctival implantation site showed that 
the fibrils became encapsulated by a thin capsule that was surrounded by fibroblasts and only a few 
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immune competent cells indicating a mild tissue reaction to a foreign material. No granulocytes were 
determined, recognizable by granulae and segmented nuclei. Furthermore no multinucleated giant cells 
were detected. Only some areas with small accumulations of lymphocytes and macrophages, 
discernible by their round shape and big nuclei, could be identified. No cells were observed in direct 
contact or attached to the fibrils indicating that this particular PEA will not support cell attachment or 
growth and therefore the polymer keeps good promise in variety of medical applications where cell 
attachment or growth is not desirable. 
3.6. Fundus and Retinal Morphology after Intravitreal Implantation of PEA Microfibrils 
Implantation into the vitreous humor was accomplished by injecting the fibrils through a 26 G 
needle transsclerally and as expected the procedure was simple and uneventful. Fibrils implanted in the 
vitreous humor remained within the vitreous humor body throughout the eight weeks of the experiment 
(Figures 11 and 12); similar to the subconjunctival implants, the intravitreally implanted fibrils became 
shorter and thicker. Fundus photographs at 1, 4 and 8 weeks show a normal eye without any evidence 
of damage, inflammation or retinal detachment (Figure 11A–C). After enucleation the eyes were 
macroscopically evaluated and photographed. Figure 12A,B are photographs of the fibrils in an 
enucleated eye at 4 and 8 weeks, respectively; note that the retina remained attached, that blood vessels 
and myelinated nerve fibrils (arrows) display no abnormalities. Gross observation of the fibrils did not 
show fast material erosion during the 8 weeks of the experiment. These results confirm the expected 
slow polymer degradation, preferable for long-term ocular drug delivery. Further research is necessary 
to determine long term degradation kinetics in vivo. 
Figure 11. (A) Fundus examination of eyes with PEA fibrils implanted intravitreally. At one 
week the fibrils are clearly visible directly behind the lens. (B) After four weeks the fibril is 
still suspended within the vitreous humor. The fundus, the papilla (black arrow), and the nerve 
(red arrow) appear normal. (C) At eight weeks after implantation the PEA fibrils (white 
arrows) are still suspended within the vitreous humor and appear intact by gross examination. 
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Figure 12. Macroscopic examination of enucleated eyes with intravitreal implants of PEA 
fibrils. Examination of enucleated eyes with intravitreal PEA fibril implants (white arrows) 
(A) four and (B) eight weeks after implantation shows an attached retina with papilla 
(black arrow) and nerve (red arrow) perfused and myelinated. 
 
Histologically the retinae of eyes with intravitreal implants were normal. No evidence of any 
inflammatory response or any alterations of the retinal architecture was apparent at 1, 4 or 8 weeks 
post-implantation (Figure 13 A–C). This indicates that if any degradation of the implanted fibrils had 
taken place, the degradation products did not damage or alter the retina (Figure 13); note the integrity 
of the photoreceptor layer (“P”) and ganglion cell layer (“G”). 
Figure 13. Histology of the retina from eyes implanted with PEA fibrils intravitreally. At 
(A) one, (B) four, and (C) eight weeks after intravitreal implantation the retina is normal 
with no evidence of any alteration. Note a normal and intact photoreceptor layer (“P”) and 
ganglion cell layer (“G”). Scale bar, 100 µm. Magnification, 200×. 
 
4. Conclusions 
Herein, we show that PEA is a biocompatible and biodegradable polymer. In vitro and in vivo 
analyses unveiled the promising properties of PEA polymers for ophthalmic purposes. SEM of PEA 
fibrils incubated with chymotrypsin confirmed the previous reports that fibrils degrade via surface 
erosion mechanism enabling new approaches towards development of vehicles for sustained and 
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controlled drug release. The change of shape in vitreous humor would offer an additional advantage 
for implantation in ocular tissues such as diminished side effects and discomfort related to implant 
size. In vivo implantation showed excellent tissue biocompatibility and tolerance in rabbit eyes. Future 
work will analyze the pharmacokinetics of drug release from drug loaded PEA microfibrils. Taken 
together, the results presented here indicate that PEA fibrils are promising polymers for controlled long 
term drug release in the ocular environment. 
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